Shots:

• The approval was based on the P-III (ENSEMBLE) study to evaluate the COVID-19 vaccine in 43783 patients aged ≥18yrs. with COVID-19
• The results showed 85% vaccine efficacy in preventing severe disease & demonstrated protection against COVID-19 related hospitalization & death @28 days after vaccination while 40% of patients had comorbidities associated with an increased risk for progression to sev. COVID-19
• The vaccine is well suited for 2yrs. at -25°C to -15°C & 6mos. at temp. of 2 to 8°C. Additionally, J&J’s COVID-19 vaccine will utilize the AdVac vaccine platform to develop & manufacture EC approved Ebola vaccine regimens and this platform is also used for Zika, RSV, and HIV vaccines

Ref: J&J | Image: J&J